ERBB2 and breast carcinoma: In breast cancer, inhibitors targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and cyclin-dependent kinases (CDKs) have emerged as valuable therapeutic options [12,13].